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Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often
indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical
tests and radiological investigations, the complexity of surgical options and the variety of medical
treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally
achieved through an organized network. The present study describes currents concepts in the man-
agement of these tumours as well as an insight into the challenges of delivering the pathway in and
outside a Network.
© 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
With a European annual incidence of slightly less than
1:100 000 and comprising 8% of pancreatic tumours [1], pancre-
atic neuroendocrine neoplasms (PanNENs) are considered a very
rare entity. Despite their rarity though, they have allured
remarkable scientiﬁc attention and research resources. This is of
course because rare medical conditions require exquisite efforts
from various biomedical specialties, often beyond geographical
limitations, with increasing requirements in terms of time,
funding and dedication. But PanNENs also owe part of the focus
they have earned to the signiﬁcantly long survival that can be
achieved, particularly compared to other tumours of the foregut,
especially of the pancreas. In a clinical setting, patients with non-
metastatic disease and completely resected primary tumours can
have a survival of almost up to 100% and even in cases of liver
metastases, a long-term survival has been reported [2]. The rarity
of these tumours and their different biological behaviour, which
ranges from indolent to very aggressive, pose inevitable chal-
lenges in the diagnosis and in the treatment of PanNENs. In thissplantation, Royal Free Hos-
is).
on for Cancer Surgery, and the Eur
dis PM, et al., Treatment c
of Surgical Oncology (2018),article an overview of these pathways is presented, highlighting
the difﬁculties encountered within and outside a Network. A
description is also provided of the outcome of European patients
with a new diagnosis of PanNENs, during the period 2000e2007,
with data deriving from population-based cancer registries
contributed to the RARECAREnet project [3].
The RARECAREnet survival data
The European burden of rare cancers was estimated by the
RARECAREnet projects [3]. Among the 198 rare tumours deﬁned by
the project, four GEP NET entities were included as clinically
distinct entities. PanNENs were 15% of all GEPNET [3]. Table 1
shows survival in PanNENs by year since diagnosis, and 5-year
relative survival by sex, age and morphology subgroup. An anal-
ysis was performed of 4108 cases diagnosed during 2000e07 in 94
European countries that contributed data to the RARECAREnet
project [3]. Survival was 66, 49 and 41% at 1, 3 and 5 years after
diagnosis respectively. Outcome was signiﬁcantly better in women
than men (50% versus 37%) and reduced markedly with the
increasing age. Five-year survival rate was 66% in <25 aged patients
and reduced to 31% in patients older than 65 years. Well differen-
tiated, functioning endocrine carcinoma of pancreas showed the
best outcome, 60%. The non-functioning tumours and the poorly
differentiated ones showed intermediate outcome: 48% and 40%,opean Society of Surgical Oncology. All rights reserved.
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Table 1
Survival in European patients with PanNEN tumours by sex, age and type of neuroendocrine tumour, diagnosed 2000e07 [3].
Number of cases Relative survivala 95% CI
Overall 1-year 4108 67.4% 65.9%e68.8%
3-year 4108 51.0% 49.3%e52.7%
5-year 4108 42.9% 41.0%e44.8%
Sex Male 2156 36.7% 34.2%e39.2%
Female 1952 49.6% 46.9%e52.3%
Age <24 39 66.3% 48.0%e79.4%
25e64 2449 49.0% 46.7%e51.3%
65þ 1620 31.0% 27.9%e34.0%
PanNEN type Well differentiated/non-functional 858 48.2% 44.0%e52.3%
Well differentiated/functional 331 60.1% 53.5%e66.2%
Poorly differentiated 2780 39.9% 37.7%e42.2%
Mixed 139 27.1% 18.3%e36.7%
a For sex, age and type of neuroendocrine tumour subtypes, 5-year relative survival is presented.
P.M. Lykoudis et al. / European Journal of Surgical Oncology xxx (2018) 1e62respectively. The mixed endocrine-exocrine carcinoma had poor 5-
year survival (27%) (see Table 2).Diagnostic and therapeutic challenges of NEN
Classiﬁcations of PanNENs is complex. The WHO classiﬁcation
divides these tumours into functional (28% of all PanNENs e
Table 1) and non-functional, which comprise about 72% of all
PanNENs. PanNENs can also be classiﬁed according to the European
Neuroendocrine Tumour Society (ENETS) (Table 3). Well differen-
tiated tumours (also called Low Grade or G1) are characterized by
cellular monomorphism, good differentiation, a low mitotic rate, a
Ki67 < 3% and absence of necrosis. Tumours of intermediate fea-
tures are called G2 or Intermediate Grade with a Ki-67 between 3%
and 20%, while high Grade/G3 tumours are characterized by cells
that vary signiﬁcantly in size, shape and nuclear density, with a
high mitotic rate, poor differentiation and a Ki67 > 20% [4]. The
latter comprise now a category different from neuroendocrine
carcinomas, which are by deﬁnition poorly differentiated, but fulﬁl
other criteria of malignant tumours as well, as recently proposed by
the ENETS [5].Table 2
Most common functional PanNENs, with main symptoms, anatomical location, malignan
Tumour Manifestation Locati
Gastrinoma (Zollinger-
Ellison syndrome)
Diarrhoea, peptic ulcers 60% p
Insulinoma Hypoglycaemia, seizures, unconsciousness 99e1
Glucagonoma Migratory necrolytic rash, anaemia,
thromboembolic events
99e1
VIPoma Severe diarrhoea, electrolyte disorders 90% p
Somatostatinoma Diabetes, steatorrhoea 56% p
GRFoma Acromegaly 30% p
ACTHoma ACTH 4e16
Table 3
ENET Classiﬁcation of PanNENs according to histopathological characteristics. NET¼Neuro
from Falconi et al., 2012 [3]).
Biological behaviour WHO Classiﬁcation (2000) WHO Classiﬁcation (2010) M
Benign Well-differentiated
endocrine tumour
NET G1 or NET G2 e
Benign or low-grade
malignant
Well-differentiated
endocrine tumour
NET G1 or NET G2 e
Low-grade malignant Well-differentiated
endocrine carcinoma
NET G1 or G2 þ
High-grade malignant Poorly-differentiated
endocrine carcinoma
NEC or G3 þ
Please cite this article in press as: Lykoudis PM, et al., Treatment c
neuroendocrine tumours, European Journal of Surgical Oncology (2018),Patients with PanNENs will initially present either with symp-
toms related to a functional tumour or with the space-occupying
effects caused by non-functioning tumours. Many are found inci-
dentally whilst imaging is performed for non-related symptoms; a
proportion of these patients might present with symptoms related
to secondary deposits in other organs. PanNENs can also develop in
up to 80% of patients diagnosed with Multiple Endocrine Neoplasia
(MEN) and speciﬁcally MEN1 syndrome [6]. Other familial syn-
dromes that are associated with the development of PanNENs are
von HippeI-Lindau, Tuberosclerosis and neuroﬁbromatosis, with
the latter being associated with worse prognosis [7]. Serum Chro-
mogranin A (CgA) is the most commonly used biomarker and has
been found to correlate with prognosis [8], but its diagnostic value
was questioned during the latest revision of relevant guidelines
issued by the National Comprehensive Cancer Network (NCCN) [9].
The biochemical tests which are needed to rule out a functional
tumour include the hormone that the tumour is expected to pro-
duce, such as insulin, pro-insulin, C-peptide and anti-insulin anti-
bodies for insulinomas, or glucagon, somatostatin, VIP and gastrin
for the corresponding tumours. Recent advances include NETest,
which assesses the circulating tumour transcripts and is shown
to be associated with response to treatment with Somatostatincy likelihood and incidence. (Adapted with permission from Jensen et al., 2012[38]).
on Malignancy Incidence per million
ancreas, 30% duodenum 60e90% 0.5e3
00% pancreas 5e15% 1e3
00% pancreas 60e80% 0.01e0.1
ancreas 80% 0.05e0.2
ancreas, 44% duodenum/jejunum 50e60% <0.01
ancreas, 54% lung, 7% jejunum 30% <0.01
% pancreas >90% <0.01
endocrine tumour, NEC¼ neuroendocrine carcinoma. (Reproduced with permission
etastases Invasion Tumour size, cm Angio-invasion Ki67, %
e 2 e Usually around 2
e >2 ± Usually around 2
þ Any þ Usually >2
þ any þ >20
hallenges in and outside a specialist network setting: Pancreatic
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tumour cells [11] but these still need to be validated.
Several imaging modalities play a signiﬁcant role in
the diagnosis and staging process. Contrast enhanced Computed
Tomography (CT) scans with arterial and venous phases comprise
the cornerstone of investigation of pancreatic tumours, being the
basis of current staging. However, since PanNENs can be very
small and isodense, the sensitivity of this modality can be as low
as 30% for primary tumours [12,13]. Magnetic Resonance Imaging
(MRI), with speciﬁc sequences that enhance the accuracy for
small lesions in the pancreas, have led to an increasing enthu-
siasm in favour of this modality. A recent study demonstrated
that MRI can discriminate between Low/Intermediate tumours
and High Grade tumours, with a sensitivity of 72.3% and a spec-
iﬁcity of 91.6% [14]. Endoscopic Ultrasonography (EUS) is regar-
ded as a particularly accurate modality for the assessment of the
primary tumour as well to assess local lymph node involvement,
allowing to locate tumours and obtain specimen for cytological or
histological examination, with an adequacy rate of over 80% [15].
The diagnostic value of the method can be increased when ul-
trasonographic contrast is administered, as it demonstrated the
different vascularization pattern between the tumour and
the normal pancreatic parenchyma, while it has been suggested
that it can also differentiate between PanNENs and pancreatic
adenocarcinoma [16].
A deﬁnite challenge is the availability of the best and most ac-
curate functional images from Nuclear Medicine departments. So-
matostatin Receptor Scintigraphy offers a powerful differential tool
for the discrimination of PanNENs and other pancreatic neoplasms.Table 4
Sensitivities of Imaging modalities for PanNENs.
Modality Sensitivity
Ultrasonography 20e80%
Computed tomography 64e94%
Magnetic resonance imaging 74e100%
Endoscopic ultrasonography 80e94%
PETs 50e80%
Abdomin
Abdominal 
SRS or 68G
Resectable disease
Surgery ±IOUS
Follow-up: CT/SRS
US endoscopy/hepatocyte-specific MRI
EUS(±EUS-FNAC/B)
Fig. 1. Diagnostic algorithm for the radiological investigation of PanNENs. US¼Ultrasonogr
opsy, CT¼Computed tomography, MRI ¼ Magnetic Resonance Imaging, SRS¼Somatostat
permission from Falconi et al., 2012[3]).
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neuroendocrine tumours, European Journal of Surgical Oncology (2018),Diagnostic accuracy has been improving over the last years along
with the advances in the used isotopes, with the most recent
68GaDOTA-TATE, 68Ga-DOTA-1Na13, and 68Ga-DOTA-NOC
demonstrating signiﬁcantly higher spatial resolution and enhanced
tumour-to-background contrast [17]. It is evident from the above,
that each modality has limitations in terms of sensitivity and
speciﬁcity (Table 4), thus optimal diagnostic approach consists of
combinations of the aforementionedmodalities (Fig.1), with a view
to identify the primary tumour, target it for biopsy, and complete
tumour staging (Table 5).
Surgery remains the cornerstone of treatment of PanNENs,
whether it aims to control symptoms, resect the radiologically
detectable disease, or debulk it (usually aiming to remove >90% of
visible disease) with a view to improve response to further treat-
ment. The aim of the pancreatic endocrine surgeon is to completely
resect the primary tumour with preservation of the maximum
amount of parenchyma, and thus to minimize the risk for post-
operative exocrine or endocrine insufﬁciency.
A technical challenge is the development of pancreatic ﬁstulas
which was reported in almost 23% of patients undergoing pancre-
atic resection for PanNENs as opposed to 17% in patients who had
similar operations for other pancreatic malignancies [18]. This
higher rate can be attributed to the relative soft and friable
pancreas of patients with PanNENs, but also to the fact that enu-
cleations are signiﬁcantly more frequently performed in these pa-
tients than in patients with other pancreatic pathologies. A recent
review has summarized the favourable prognostic criteria that
include age of less than 55 years, liver involvement of less than
50%, resection of the primary tumour prior to transplantation,
stable disease for at least 6 months and good differentiation
(Ki67% < 10%), with the latter being associated with a 5-year sur-
vival of 90% [19]. Many of these surgical options would not be
appropriate for other malignancies and can be controversial even
for the most indolent PanNENs, suggesting that it is often the
knowledge of the biological behaviour and natural history of these
tumours which dictate the best therapeutic approach. This require
a dedicated panel of specialists with a speciﬁc interest in PanNENs
rarely available outside dedicated centres, which is equally crucial
in the medical and radiological management of PanNENs.al US
CT/MRI
a PET
Unresectable disease
EUS or US-guided FNAC/B
aphy, EUS ¼ Endoscopic Ultrasonography, FNAC/B¼Fine needle aspiration cytology/bi-
in Receptors Scintigraphy, IOUS¼Intra-operative ultrasonography. (Reproduced with
hallenges in and outside a specialist network setting: Pancreatic
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Table 5
The AJCC/UICC and ENETS staging of Pancreatic Neuroendocrine Neoplasms.
Stage 0 Tis Carcinoma in situ
N0 No involved
regional lymph nodes
M0 No distant
metastasis
Stage IA T1 Tumour limited to the pancreas, 2 cm
Stage IB T2
AJCC: Tumour limited to the
pancreas, >2 cm
ENETS: Tumour limited to the
pancreas, 2e4 cm
Stage IIA T3
AJCC: Tumour extends beyond the
pancreas, without vascular involvement
ENETS: Tumour conﬁned to pancreas,
>4 cm, invasion of duodenum or bile duct
Stage IIB Any T N1 Regional lymph
node metastasis
Stage III T4 Any N
AJCC: Vascular involvement ENETS: Invasion of adjacent
organs or vessels
Stage IV Any T M1 distant
metastasis
P.M. Lykoudis et al. / European Journal of Surgical Oncology xxx (2018) 1e64Medical treatment aims to manage symptoms, to downsize/
downstage the disease with a view to surgical resection, to manage
disease progression or to palliate. Syndrome-related symptoms are
managed in the acute setting with blood glucose control in case of
insulinomas and glucagonomas, volume and electrolyte loses in
VIPomas, gastric pH control in gastrinomas and in all cases with
somatostatin analogues that block the somatostatin receptors and
reduce secretion of active peptides. Somatostatin analogues also
exert an antiproliferative role in PanNETs, improving overall sur-
vival by delaying tumour growth [20]. Streptozocin and ﬂuorouracil
have been the backbone of chemotherapy regiments for many
years, with a response rate of over 60% and increase of survival by
more than 1 year [21,22]. Chemotherapeutic regimens vary, ac-
cording to tumour features, with cisplatin and etoposide being used
for higher grade lesions [23] and temozolomide with capecitabine
for well differentiated tumours [24]. Liposomal and conventional
doxorubicin have also been used whereas addition of the anti-
angiogenesis monoclonal antibody Bevacizumab has been associ-
ated with a better progression free survival [25]. Recent improve-
ments include the use of Everolimus, an mTOR inhibitor that
demonstrated increase of survival 6.3 months, though not statis-
tically signiﬁcant [26], while the addition of pasireotide does not
demonstrate any additional beneﬁt [27]. Another agent that has
recently demonstrated signiﬁcant results is the tyrosine kinase
inhibitor Sunitinib malate, which doubled the progression free
survival, and was also associated with statistically signiﬁcantly
improved overall survival [28].
Several other modalities have been used to manage neuroen-
docrine tumours. Radionuclide therapy is being delivered to so-
matostatin receptors in an attempt for a focused irradiation of
PanNENs, either in the form of Peptide Receptor Radionuclide
Therapy (PRRT) or Selective Internal Radiation Therapy (SIRT),
mainly aiming to stabilize the disease, with a major response rate
of about 60% and inhibition of progression in 85% [29]. Liver
metastases not amenable to surgical treatment have been
managed with hepatic artery embolization aiming for mechanical
obstruction of perfusion or also local delivery of high concentra-
tion of cytotoxic agents such as streptozocin and ﬂuorouracil but
also mitomycin C and cisplatin. This modality yields a highly
successful control of symptoms of up to 100% and a partial
response that can be up to 80% [2]. Finally, radiofrequency and
microwave ablation have also been employed with symptom
control rate of >90% and mean overall survival of 73 months [30],
either in combination with surgical resection, or as an alternative
in patients that were not deemed ﬁt for surgery and tumours not
amenable to surgical resection.
Medical treatment is frequently available in secondary and ter-
tiary institutes but complex interventional radiology is frequentlyPlease cite this article in press as: Lykoudis PM, et al., Treatment c
neuroendocrine tumours, European Journal of Surgical Oncology (2018),carried out in dedicated centres, especially for procedures requiring
the input of nuclear medicine specialists such as for SIRT or PRRT.
Management within a network
Outcomes following management of any medical condition
depend heavily on the expertise of healthcare delivery team. This
can be quite challenging when it comes to diseases with relatively
low occurrence, such as PanNENs. In 2013, about 1500 new di-
agnoses of PanNENs were estimated in Europe (EU28) [3]. The so-
lution to this problem is usually centralization of patient's care and
resources, so that NET Units can maintain a workload that gua-
rantees adequate experience and enhanced outcomes. A systematic
review on upper gastrointestinal surgery, demonstrated a clear
beneﬁt in terms of outcomes for high volume centres and sur-
geons [31], whilst another study focusing particularly on pan-
creaticoduodenectomy demonstrated improved overall resection
rates and higher R0 resection rates when centralization was
implemented [32]. Centralization has not been studied so far spe-
ciﬁcally in PanNENs, however, the expertise required is similar to
the one required to manage other hepato-pancreato-biliary ma-
lignancies. Although it is extremely difﬁcult to deﬁne a minimum
number of patients per centre, it seems reasonable to support that
most countries would need 2e10 Units to maintain expertise [33].
Patients with PanNENs can present with a remarkable variety of
symptoms, thus the ﬁrst clinician that they see might be a general
practitioner, a family doctor, an Accident & Emergency doctor, a
gastroenterologist, a general surgeon, an endocrinologist or even a
radiologist, if in lines with the local healthcare service they can
individually arrange a radiological investigation [34]. Quite
frequently, the ﬁrst working diagnosis is not this of an endocrine
tumour, thus the next steps might be advised by any of the above
specialties, as well as oncologists and hepato-pancreato-biliary
surgeons. It is of course impossible for a PanNET Unit to exist
wherever these specialists practice, but these Units need to main-
tain excellent communication and bidirectional feedback with local
primary and secondary healthcare structures, so that an adequate
level of awareness is maintained and all physicians are familiar
with the ﬁrst steps of relevant pathways.
Speciﬁc imaging investigation of PanNENs includes sophisti-
cated modalities that require a certain level of radiological exper-
tise. The histopathological features of these tumours are very
speciﬁc and it is essential that involved pathologists are explicitly
familiar with this entity. Surgical treatment of PanNENs usually
involves major liver and pancreatic surgery and in some cases liver
transplantation, which mandates management in a Hepato-
Pancreato-Biliary Unit. Endocrine management of relevant symp-
toms can be very challenging and should thus be conducted byhallenges in and outside a specialist network setting: Pancreatic
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PanNENs. Systemic treatment is evolving rapidly, differs signiﬁ-
cantly from the systemic treatment of other neoplasms and thus
requires an Oncology team with particular interest in the man-
agement of these tumours. It becomes clear from the above that a
GI NENs unit needs to comprise of key medical specialties with a
special interest in these lesions. However, since pancreatic sur-
gery is very demanding with a signiﬁcant higher mortality and
morbidity rate in low-volume centres in comparison to high-
volume centres, speciﬁc expertise is required.
Following treatment, patients with PanNENs will return to their
local community, and in many cases it might be practically
impossible for the follow-up to be carried in the PanNEN unit that
delivers treatment. It is then necessary for PanNEN units to have an
outreach team, consisted of Clinical Nurse Specialists or local Pri-
mary Care practitioners, than can follow patients up closely, ac-
cording to relevant guidelines, and provide feedback to relevant
Units. It becomes thus evident that the optimal treatment of pa-
tients with PanNENs requires a robust network of medical practi-
tioners, connecting local primary and secondary services, with few
large PanNEN Units that consult on patients' diagnostic evaluation
and treatment, and audit current practice and outcomes. The above
two-way communication can be facilitated through regional and
superregional video-linked multidisciplinary meetings on a
frequent basis. Moreover, PanNENs Units need to communicate
with each other, to increase the collective experience, to organize
trials in order to delineate all grey areas, and eventually to revise
relevant guidelines.
This admirable effort does not come without costs of course.
Potentially the greatest challenge is funding. Centralization of pa-
tients in few Units requires that these Units are able to bear the
costs of very sophisticated and as such very expensive diagnostic
and therapeutic techniques. From an administrative point of view,
this arrangement requires a large number of staff providing ofﬁce
support to both physicians and patients, facilitating communica-
tion, data collection and maintenance, organization of meetings
and educational events. In a network that involves many practi-
tioners in different levels of healthcare and oftenworking remotely
from each other, accurate communication and documentation can
be very challenging in order to avoid confusion and teleconference
infrastructures can be imperative.
Within the UK, PanNENs units are closely attached to hepato-
pancreato-biliary units, but cover is provided beyond the existing
regional referral system, in order to tackle all the aforementioned
difﬁculties. At European level, the European Neuroendocrine
Tumour Society (ENETS), recognized the need for an international
network of Neuroendocrine centres in 2007, and one year later an
accreditation process began which by now has accredited 37 Cen-
tres of Excellence across Europe.
According to the Society, this effort has yielded improved
cooperation between centres and improved quality of clinical trials.
The involved centres have reported improved patient documenta-
tion, multidisciplinary team discussions, follow-up and quality
control, while the collaboration of Centres of Excellence has also
yielded valuable educational activities. It is without doubt difﬁcult
to quantify, measure and assess the improvement in patient-related
outcomes, and the Society identiﬁes this question as a key point at
the moment, however the current experience of Centres of Excel-
lence is very encouraging. The ENETS should consider the outcome
inequalities in Europe [35], in term of outcome and consequently
organization, the latter depends of the size of the population
therefore of the expertise of clinicians and from the cancer or rare
disease national programs [35]. Survival for patients with NET from
population studies largely varied across country. For the group of
GEP (including digestive system and pancreas) well differentiatedPlease cite this article in press as: Lykoudis PM, et al., Treatment c
neuroendocrine tumours, European Journal of Surgical Oncology (2018),not functioning endocrine carcinoma, 5-year survival ranged from
more that 70% in the majority of the Nordic countries and Centre of
Europe (between 70 and 83%) to 60% or less in Lithuania, Latvia and
Bulgaria [3]. The reason for Bulgaria was even the lack of patho-
logical facilities for accurately diagnosing rare neuroendocrine tu-
mours [3]. One major issue remains the quality of diagnosis, mainly
due to inadequate facilities and abilities to diagnose many complex
rare cancers. The deﬁnition of national and international pathways
for second opinions from expert pathologists was also deemed
important. Having this in mind, the European Reference Networks
should offer a good opportunity to improve pathologists' training
through dedicated training schemes and fellowships across Europe.
Cancer registration remains vital for monitoring progress in rare
cancer diagnosis and treatment for these patients.Conclusion
Pancreatic neuroendocrine neoplasms are an entity with
particular epidemiologic and histological features, that require
complex diagnostic and treatment strategies, optimally delivered
by multidisciplinary teams with special interest and expertise. The
challenges that emerge from this statement are best managed
within a network of specialized Units, such as the Centres of
Excellence currently accredited and supervised by the European
Neuroendocrine Tumour Society, with an ultimate scope to
continuously improve delivered care to patients with PanNENs.Conﬂict of interest
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